加载中
NASDAQHealthcareDrug Manufacturers - General
最新数据
US$0.7054
−US$0.0401 · -5.38%
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.
收盘时
US$0.7054
−US$0.0401 · -5.38%
盘后
US$0.70
−US$0.0054 · -0.77%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.
日内区间
当前US$0.7054
52周区间
当前US$0.7054
盘中时间采用ET。市场数据可能有所延迟。
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.
日内区间
当前US$0.7054
52周区间
当前US$0.7054
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 171.98万 USD | 330.56万 USD | 157.3万 USD | 235.15万 USD | 68.44万 USD |
| 销售、一般及管理费用 | 877.33万 USD | 471.28万 USD | 649.95万 USD | 299.21万 USD | 77.01万 USD |
| 营业费用 | 1049.31万 USD | 801.83万 USD | 852.6万 USD | 704.79万 USD | 215.22万 USD |
| 利息收入 | 9.89万 USD | — | — | — | — |
| 利息支出 | — | 16.57万 USD | 345.63万 USD | 1.03万 USD | 2.44万 USD |
| 折旧和摊销 | — | — | — | 704.79万 USD | 215.22万 USD |
| 营业利润 | −1049.31万 USD | −801.83万 USD | −852.6万 USD | −704.79万 USD | −215.22万 USD |
| 净利润 | −1044.25万 USD | −785.27万 USD | −1198.23万 USD | −705.82万 USD | −217.65万 USD |
公司数据更新于 2026年10月13日。
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
